Claude M. Wischik

10.8k citations

123 papers · 8.2k indexed · 4 hit papers · h-index 42

Physiology top 0.1%
- Alzheimer's disease research and treatments 98
Neurology top 0.5%
- Parkinson's Disease Mechanisms and Treatments 16
Cellular and Molecular Neuroscience top 0.5%
- Neuroscience and Neuropharmacology Research 22
- Genetic Neurodegenerative Diseases 11
Biological Psychiatry top 1%
Pharmacology top 0.2%
- Cholinesterase and Neurodegenerative Diseases 22
Molecular Biology
- Prion Diseases and Protein Misfolding 29
- Protein Structure and Dynamics 8
Psychiatry and Mental health
- Dementia and Cognitive Impairment Research 16

Co-authors: Charles R. Harrington R. Anthony Crowther M Novák A. Klug Patricia C. Edwards Martin Roth John E. Walker Michel Goedert
Cited by: Physiology Neurology Cellular and Molecular Neuroscience
Journals: Proceedings of the National Academy of Sciences (6 papers)The Lancet (2 papers)Journal of Biological Chemistry (2 papers)
Partner nations: United Kingdom Germany United States

In The Last Decade

Claude M. Wischik

120 papers receiving 8.0k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2016 Biomolecules
2016 The Lancet
1988 Proceedings of the National Academy of Sciences
1988 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Claude M. Wischik

Since Specialization

Citations

This map shows the geographic impact of Claude M. Wischik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claude M. Wischik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claude M. Wischik more than expected).

Fields of papers citing papers by Claude M. Wischik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claude M. Wischik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claude M. Wischik. The network helps show where Claude M. Wischik may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Claude M. Wischik, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Claude M. Wischik Line = papers co-authored together Claude M. Wischik links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effects of hydromethylthionine mesylate and rivastigmine in a pharmacological mouse model of Alzheimer’s disease Behavioural Pharmacology ·Lianne Robinson,Jack Bray,Valeria Melis,Charles R. Harrington,Claude M. Wischik,Gernot Riedel	2025	0
2	High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease Alzheimer s Research & Therapy ·Mohammad Arastoo,Lewis K. Penny,Richard Lofthouse,Aya Abdallah,Anna Abrahamsson,Pietro Marini,Valeria Melis,Gernot Riedel,Charles R. Harrington,Claude M. Wischik,A.J. Porter,Soumya Palliyil	2024	3
3	Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer’s-like Tauopathy Mouse Model Cells ·Maciej Zadrożny,Patrycja Drapich,Anna Gasiorowska-Bien,Wiktor Niewiadomski,Charles R. Harrington,Claude M. Wischik,Gernot Riedel,Grażyna Niewiadomska	2024	7
4	A Meta-Analysis on Presynaptic Changes in Alzheimer’s Disease Journal of Alzheimer s Disease ·Anne Anschuetz,Karima Schwab,Charles R. Harrington,Claude M. Wischik,Gernot Riedel	2023	5
5	Significant dose‐dependent reduction in neurofilament light chain concentration in plasma with oral tau aggregation inhibitor hydromethylthionine mesylate Alzheimer s & Dementia ·Claude M. Wischik,B. Schelter,Lewis K. Penny,S. K. Miller,Richard G. Stefanacci,Amanda Heslegrave,Henrik Zetterberg	2023	2
6	Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate The Journal of Prevention of Alzheimer s Disease ·Claude M. Wischik,Peter Bentham,Serge Gauthier,Stacey Miller,Karin A. Kook,B. Schelter	2022	28
7	Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementia Brain Communications ·Vesna Vuksanović,Roger T. Staff,Suzannah Morson,Trevor Ahearn,Luc Bracoud,Alison D. Murray,Peter Bentham,Christopher Kipps,Charles R. Harrington,Claude M. Wischik	2021	4
8	Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia Journal of Biological Chemistry ·Nora Lemke,Valeria Melis,Dilyara Lauer,Mandy Magbagbeolu,Boris Neumann,Charles R. Harrington,Gernot Riedel,Claude M. Wischik,Franz Theuring,Karima Schwab	2020	9
9	Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategiesbreakdown → Biomolecules ·Goran Šimić,Mirjana Babić Leko,Selina Wray,Charles R. Harrington,Ivana Delalle,Nataša Jovanov Milošević,Danira Bažadona,Luc Buée,Rohan de Silva,Giuseppe Di Giovanni,Claude M. Wischik,Patrick R. Hof	2016	517
10	Assays for the Screening and Characterization of Tau Aggregation Inhibitors Methods in molecular biology ·Janet E. Rickard,David A. Horsley,Claude M. Wischik,Charles R. Harrington	2016	8
11	Monoaminergic neuropathology in Alzheimer’s disease Progress in Neurobiology ·Goran Šimić,Mirjana Babić Leko,Selina Wray,Charles R. Harrington,Ivana Delalle,Nataša Jovanov Milošević,Danira Bažadona,Luc Buée,Rohan de Silva,Giuseppe Di Giovanni,Claude M. Wischik,Patrick R. Hof	2016	227
12	Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease Journal of Alzheimer s Disease ·Claude M. Wischik,Roger T. Staff,Damon Wischik,Peter Bentham,Alison D. Murray,John M. D. Storey,Karin A. Kook,Charles R. Harrington	2015	199
13	Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer’s Disease Journal of Pharmacology and Experimental Therapeutics ·Thomas C. Baddeley,Jennifer McCaffrey,John M. D. Storey,J. Cheung,Valeria Melis,David A. Horsley,Charles R. Harrington,Claude M. Wischik	2014	98
14	P4‐347: Tau aggregation inhibitor (TAI) therapy with rember^™ arrests the trajectory of rCBF decline in brain regions affected by Tau pathology in mild and moderate Alzheimer's disease (AD) Alzheimer s & Dementia ·Roger T. Staff,Trevor Ahearn,Alison D. Murray,Peter Bentham,Kwang Meng Seng,Claude M. Wischik	2008	9
15	α-Synuclein Inclusions in Alzheimer and Lewy Body Diseases Journal of Neuropathology & Experimental Neurology ·Elizabeta B. Mukaetova‐Ladinska,J. Hurt,Ross Jakes,John H. Xuereb,William G. Honer,Claude M. Wischik	2000	33
16	Apolipoprotein E Genotype in the Prediction of Cognitive Decline and Dementia in a Prospectively Studied Elderly Population Dementia and Geriatric Cognitive Disorders ·Carol Brayne,Charles R. Harrington,Claude M. Wischik,Felicia A. Huppert,Lei Chi,John H. Xuereb,Daniel O’Connor,Eugene S. Paykel	1996	35
17	Alterations in Tau Protein Metabolism during Normal Aging Dementia and Geriatric Cognitive Disorders ·EB Mukaetova-Ladinska,Charles R. Harrington,Martin Roth,Claude M. Wischik	1996	35
18	Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients The Lancet ·Charles R. Harrington,Claude M. Wischik,F.K. McArthur,Geoffrey A. Taylor,J.A. Edwardson,J. Candy	1994	99
19	Biochemical and anatomical redistribution of tau protein in Alzheimer's disease. PubMed Central ·EB Mukaetova-Ladinska,Charles R. Harrington,Martin Roth,Claude M. Wischik	1993	90
20	A Progressive Deposition of Paired Helical Filaments (PHF) in the Brain Characterizes the Evolution of Dementia in Alzheimerʼs Disease. Journal of Neuropathology & Experimental Neurology ·Raúl Mena,Claude M. Wischik,Michal Novák,César Milstein,A. Claudio Cuello	1991	45

About Claude M. Wischik

Claude M. Wischik is a scholar working on Physiology, Neurology and Cellular and Molecular Neuroscience, having authored 123 papers that have together received 8.2k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (98 papers), Prion Diseases and Protein Misfolding (29 papers), Neuroscience and Neuropharmacology Research (22 papers), Cholinesterase and Neurodegenerative Diseases (22 papers), Parkinson's Disease Mechanisms and Treatments (16 papers), Dementia and Cognitive Impairment Research (16 papers), Genetic Neurodegenerative Diseases (11 papers) and Protein Structure and Dynamics (8 papers). The work is most often cited by research in Physiology (6.3k citations), Neurology (1.4k citations) and Cellular and Molecular Neuroscience (2.0k citations). Claude M. Wischik has collaborated with scholars based in United Kingdom, Germany and United States. Frequent co-authors include Charles R. Harrington, R. Anthony Crowther, M Novák, A. Klug, Patricia C. Edwards, Martin Roth, John E. Walker, Michel Goedert, John M. D. Storey and Ross Jakes. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact